Doxorubicin Resistance in Pancreatic Tumor Cells
Author Information
Author(s): VN Verovski, DL Van den Berge, MM Delvaeye, RJ Scheper, WJ De Nevel, GA Storme
Primary Institution: Free University Brussels
Hypothesis
G protein-dependent drug transport pathways may contribute to low-level doxorubicin resistance.
Conclusion
The study suggests that brefeldin A-sensitive mechanisms play a role in low-level doxorubicin resistance in pancreatic tumor cells.
Supporting Evidence
- The PSN1/ADR cells showed multidrug resistance not conferred by P-glycoprotein.
- Resistance was associated with overexpression of lung resistance-related protein (LRP).
- Doxorubicin cytotoxicity was enhanced by brefeldin A and verapamil in resistant cells.
Takeaway
Some cancer cells can resist a drug called doxorubicin, and this study found that a substance called brefeldin A can help understand how this happens.
Methodology
The study involved stepwise selection of pancreatic tumor cells in doxorubicin and analysis of drug accumulation and resistance mechanisms.
Limitations
The study primarily focuses on in vitro models, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website